@article{article, title = {{Immunogenicity and safety of AZD2816, a beta (B.1.351) variant COVID-19 vaccine, and AZD1222 (ChAdOx1 nCoV-19) as third-dose boosters for previously vaccinated adults: a multicentre, randomised, partly double-blinded, phase 2/3 non-inferiority immunobridging study in the UK and Poland}}, publisher = {{Elsevier BV}}, url = {{http://dx.doi.org/10.1016/s2666-5247(23)00177-5 }}, year = {{2023}}, month = {{9}}, author = {{Ramasamy MN and Kelly EJ and Seegobin S and Dargan PI and Payne R and Libri V and Adam M and Aley PK and Martinez-Alier N and Church A and Jepson B et al}}, doi = {{10.1016/s2666-5247(23)00177-5}}, volume = {{4}}, journal = {{The Lancet Microbe}}, issue = {{11}}, pages = {{e863-e874}}, note = {{Accessed on 2025/06/23}}}